BioSpace News Archive

Inovedis GmbH, a medical technology start-up dedicated to offering innovative solutions that contribute both to optimized patient care as well as minimizing the complexity of surgical interventions, announced the successful close of a Series A funding round totaling $4 million.

IntellxxDNA™, a leader in genomic insights, is thrilled to announce a partnership with Documenting Hope, the research arm of Epidemic Answers, a 501 nonprofit dedicated to helping children heal from chronic health conditions.

ImmuCell Corporation announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023.

ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer.

Haemonetics Corporation announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, November 2, 2023.

Envista Holdings Corporation (NYSE: NVST) (“Envista”) will report financial results for its third quarter 2023 on Wednesday, November 1, 2023.

Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

XNK Therapeutics AB announced that Anna-Karin Maltais, Chief Scientific Officer, will be speaking at the 2nd Annual Innate Killer Europe Summit in London on October 18.

The shareholders of Spago Nanomedical AB, corporate registration number 556574-5048 are hereby summoned to the Extraordinary General Meeting on Tuesday 31 October 2023, at 13.00 p.m. CET at Advokatfirman Cederquist’s premises, Hovslagargatan 3, in Stockholm.

Kyowa Kirin Co., Ltd. and Orchard Therapeutics plc announced the companies have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics for $16.00 per American Depositary Share in cash, under which Orchard shareholders will hold an additional contingent value right of $1.00 per ADS.